Literature DB >> 2792320

Hodgkin's disease and age.

L Specht1, N I Nissen.   

Abstract

506 unselected, previously untreated patients with Hodgkin's disease were treated at the Finsen Institute between 1969 and 1983. The prognostic significance of age, sex, stage, systemic symptoms, histologic subtype, number of involved nodal regions, total tumour burden (peripheral + intrathoracic nodal tumour burden, intraabdominal nodal tumour burden, and number of involved extranodal sites), pretreatment ESR, lymphocytopenia, and treatment modality were examined in multivariate analyses. The only factors of independent prognostic significance for disease-free survival proved to be treatment modality, stage, and total tumour burden, whereas age had no prognostic significance. With regard to death from Hodgkin's disease only age and total tumour burden had independent significance. The significance of age would seem to stem from the fact that some older patients could not be given adequate treatment for relapse. The present study indicates that Hodgkin's disease in older patients is not prognostically very different from Hodgkin's disease in younger patients.

Entities:  

Mesh:

Year:  1989        PMID: 2792320

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  5 in total

1.  The expression of Ki-67 and Bcl-2 in Hodgkin's lymphoma: correlation with the International Prognostic Score and bulky disease: a study by the Serbian Lymphoma Study Group (SLG).

Authors:  Ljubomir R Jakovic; Biljana S Mihaljevic; Maja D Perunicic Jovanovic; Andrija D Bogdanovic; Vesna M Cemerikic Martinovic; Tamara K Kravic; Vladimir Z Bumbasirevic
Journal:  Med Oncol       Date:  2007       Impact factor: 3.064

2.  Management of older Hodgkin lymphoma patients.

Authors:  Andrew M Evens; Jordan Carter; Kah Poh Loh; Kevin A David
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

Review 3.  The unique characteristics and management of patients over 60 years of age with classic Hodgkin lymphoma.

Authors:  Teresa V Halbsguth; Boris Böll; Peter Borchmann; Volker Diehl
Journal:  Curr Hematol Malig Rep       Date:  2011-09       Impact factor: 3.952

4.  ABVD as the treatment option in advanced Hodgkin's lymphoma patients older than 45 years.

Authors:  Bosko M Andjelic; Biljana S Mihaljevic; Ljubomir R Jakovic
Journal:  Pathol Oncol Res       Date:  2012-01-11       Impact factor: 3.201

5.  Development and validation of a prediction model for 1-year mortality among older adults with Hodgkin Lymphoma who receive dose-intense chemotherapy.

Authors:  Anita J Kumar; Jason Nelson; Angie Mae Rodday; Andrew M Evens; Jonathan W Friedberg; Tanya M Wildes; Susan K Parsons
Journal:  J Geriatr Oncol       Date:  2021-07-28       Impact factor: 3.599

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.